Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Existing research is often hampered by small sample sizes, inadequate control groups (making comparisons difficult), and lack of publication in reputable journals
BPC-157 supports this interconnected system by: Strengthening tight junctions between intestinal epithelial cells, reducing intestinal permeability (leaky gut) Modulating the enteric nervous system to normalize motility and reduce visceral hypersensitivity Regulating mucosal immune responses to prevent inappropriate inflammation against dietary and microbial antigens Conditions Treated with Oral BPC-157 Beyond Symptom Relief: Addressing Root Causes Unlike proton pump inhibitors (PPIs) that suppress stomach acid or corticosteroids that broadly dampen immunity, BPC-157 works by restoring the underlying structural and functional integrity of the gastrointestinal tract
A clinic that dismisses the peptide entirely on the basis of the failed Phase III is also overstating, in the other direction
Government of Canada
You often cant tell by visual inspection
